Bleeding prophylaxis with the investigational factor VIIIa mimetic bispecific antibody Mim8 (denecimig) was superior to ...

Today, the New England Journal of Medicine (NEJM) published 26-week results from the phase 3 FRONTIER2 trial evaluating the ...

ASH and ISTH sought to develop clinical practice guidelines on anticoagulant prophylaxis for pediatric patients who are at risk of VTE.

The phase 3, international, open-label, single-group XTEND-Kids study concluded that children with severe hemophilia A younger than 12 years benefited from treatment with efanesoctocog alfa ...

Cancer patients face a high risk for infection when undergoing cytotoxic chemotherapy and hematopoietic stem cell transplant (HSCT), particularly during the period of neutropenia. In this high-risk ...

Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in ...

Pharmacy students in the U.S. show limited knowledge of HIV prophylaxis, especially PEP, due to inadequate assessment tools. Pharmacists are pivotal in HIV prevention, but their knowledge of PrEP and ...

Awareness of venous thromboembolism has increased considerably. As a result of the Surgeon General's call to action in 2008 to prevent deep-vein thrombosis and pulmonary embolism, programs have been ...

Previous reports suggest a benefit of fluconazole prophylaxis in extremely low birth weight (ELBW) infants <1000 g. Our aim was to evaluate if limiting fluconazole prophylaxis to targeted highest risk ...